ENVB

Enveric Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website enveric.com
Employees(FY) 25
ISIN US29405E2081

Performance

-8.7%

1W

-7.79%

1M

+1.08%

3M

-41.67%

6M

-35.38%

YTD

-44.74%

1Y

Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Advanced Technical Analysis

Technical Analysis of ENVB 2024-05-10

Overview:

In analyzing the technical indicators for ENVB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.

Trend An...

See more ...

Recent News & Updates

2024-05-14 18:00
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results(Businesswire)
2024-05-13 20:00
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders(Businesswire)
2024-05-07 19:00
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids(Businesswire)
2024-05-02 05:50
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know(Zacks)
2024-04-12 00:00
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock(Zacks)
2024-03-31 22:53
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023(Investorplace)
2024-03-25 19:00
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023(Businesswire)
2024-03-18 19:00
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease(Businesswire)
2024-03-11 19:00
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets(Businesswire)
2024-02-29 01:04
Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?(Investorplace)
2024-02-28 18:00
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds(Businesswire)
2024-02-25 19:00
CORRECTION Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)(Globenewswire)
2024-02-22 19:00
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property(Businesswire)
2024-02-20 19:00
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders(Businesswire)
2024-01-02 19:00
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series(Businesswire)
2023-12-28 19:52
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market(Businesswire)
2023-12-27 19:00
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series(Businesswire)
2023-12-26 19:00
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373(Businesswire)
2023-12-19 19:00
Enveric Biosciences to Participate in Biotech Showcase 2024 During J.P. Morgan Week 2024(Businesswire)
2023-12-04 19:00
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds(Businesswire)
2023-11-28 19:00
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives(Businesswire)
2023-11-26 19:00
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry(Businesswire)
2023-11-23 19:00
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)(Businesswire)
2023-11-13 03:01
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results(Businesswire)
2023-10-30 20:00
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin(Businesswire)
2023-10-19 20:00
Enveric Biosciences to Present at the Centurion One 5th Global Summit(Businesswire)
2023-10-17 20:00
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders(Businesswire)
2023-10-10 20:00
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit(Businesswire)
2023-10-02 20:00
Enveric Biosciences Announces its Psybrary Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates(Businesswire)
2023-09-26 20:00
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry(Businesswire)

Page 1 of 4

previousnext